Diaceutics PLC on Wednesday said it has launched its new pathology engagement liaisons service, and secured a new 12-month contract worth up to $1.8 million.
The Belfast-based technology and solutions provider to the pharmaceutical and biotech industry said the new contract is with an unnamed existing customer, among one of the top twenty global pharmaceutical companies.
The contract will see Diaceutics using its newly launched PEL service to facilitate the outreach and education of laboratory pathologists for pancreatic cancer testing.
The PEL service can also in future be deployed under Diaceutics’ PMx commercialisation solution, which helps to optimise laboratory testing and patient recruitment to therapy. The service launch will increase the revenue per brand available to the company.
Chief Precision Medicine Officer Susanne Munksted said: ‘It is very exciting to continue to build our product utilising the DXRX lab network in the US. More importantly, this engagement will make a significant difference to patient lives with us working closely with our pharma customer to bring this new therapy option to patients in need.’
Shares in Diaceutics were up 5.5% at 145.00 pence each in London on Wednesday morning.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
